EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications

Areesha Moiz, Tetiana Zolotarova, Kristian B Filion, Mark J Eisenberg

American Journal of Hypertension · 01.05.2026 · 39 (5) · 611-622

DOI: 10.1093/ajh/hpaf205 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hypertension, online erschienen am 23.10.2025. Verfasst von Areesha Moiz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital/McGill University, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Blood Pressure, Hypertension, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fond de recherche du Québec-Santé, McGill University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for the treatment of type 2 diabetes and, more recently, for weight management among individuals without diabetes.

Aim

This review synthesizes the current evidence on the mechanisms by which GLP-1 RAs affect BP, their clinical effects across populations, and the implications for patient care. We discuss subpopulations who may benefit from their BP-lowering effects, identify limitations in the existing evidence, and explore future directions for research.

Results

Beyond their metabolic effects, growing evidence suggests that GLP-1 RAs produce modest reductions in BP, typically 2-5 mm Hg systolic, across diverse populations with diabetes, obesity, or at high cardiovascular risk. These reductions appear to be driven primarily by weight loss, with additional contributions from potential weight-independent mechanisms such as natriuresis, improved endothelial function, and attenuation of vascular inflammation. Although smaller in magnitude than those achieved with traditional antihypertensive drugs, the BP-lowering effects of GLP-1 RAs can translate into meaningful cardiovascular risk reduction at the population level and provide additive BP benefit when used alongside conventional therapies. Among individuals with hypertension, GLP-1 RAs are generally well tolerated, although small increases in heart rate and potential interactions with volume-regulating medications may warrant clinical attention.

Conclusion

As newer GLP-based therapies continue to emerge, a clearer understanding of their effects on BP may inform more integrated approaches to cardiometabolic care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsBlood PressureHypertensionDiabetes Mellitus, Type 2Antihypertensive AgentsHypoglycemic AgentsIncretinsHumansGlucagon-Like Peptide-1 ReceptorTreatment OutcomeAnimalsObesity

Stichwörter der Autor:innen

antihypertensiveblood pressurecardiometabolic riskglucagon-like peptide-1 receptor agonistshypertension

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 ReceptorAntihypertensive AgentsHypoglycemic AgentsIncretins

Autor:innen und Institutionen

  • Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital/McGill University, Montreal, QC, Canada.
  • Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
  • Department of Medicine, McGill University, Montreal, QC, Canada.
  • Faculty of Medicine, McGill University, Montreal, QC, Canada.
  • Division of Cardiology, Jewish General Hospital/McGill University, Montreal, QC, Canada.

Förderung

  • Fond de recherche du Québec-Santé
  • McGill University

Zitieren

APA

Moiz, A., Zolotarova, T., Filion, K. B., & Eisenberg, M. J. (2026). GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications. American Journal of Hypertension, 39(5), 611-622. https://doi.org/10.1093/ajh/hpaf205

Vancouver

Moiz A, Zolotarova T, Filion KB, Eisenberg MJ. GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications. American Journal of Hypertension. 2026;39(5):611-622. doi:10.1093/ajh/hpaf205

BibTeX
@article{Moiz2026,
  author = {Moiz, Areesha and Zolotarova, Tetiana and Filion, Kristian B and Eisenberg, Mark J},
  title = {GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications},
  journal = {American Journal of Hypertension},
  year = {2026},
  volume = {39},
  number = {5},
  pages = {611--622},
  doi = {10.1093/ajh/hpaf205}
}
Kostenlos starten →